Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | GBA1 | P04062 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyridine SCHEMBL6517120 | 1.00 | TSHR (0.53) | TSHRNAPRTTDP1ALDH1A1KCNA5 | |
| Pyridine SCHEMBL8505767 | 1.00 | TSHR (0.53) | TSHRNAPRTTDP1ALDH1A1KCNA5 | |
| Pyridine SCHEMBL3867441 | 1.00 | TSHR (0.53) | TSHRNAPRTTDP1ALDH1A1KCNA5 | |
| Pyridine SCHEMBL22472321 | 0.97 | TSHR (0.50) | TSHRNAPRTTDP1ALDH1A1KCNA5 | |
| Pyridine SCHEMBL1546704 | 0.97 | TSHR (0.50) | TSHRNAPRTTDP1ALDH1A1KCNA5 | |
| Pyridine SCHEMBL3446743 | 0.97 | TSHR (0.50) | TSHRNAPRTTDP1ALDH1A1KCNA5 | |
| Pyridine SCHEMBL28203361 | 0.95 | TSHR (0.47) | TSHRNAPRTTDP1ALDH1A1KCNA5 | |
| Pyridine SCHEMBL10387368 | 0.95 | TSHR (0.47) | TSHRNAPRTTDP1ALDH1A1 | |
| Pyridine SCHEMBL8666898 | 0.90 | TSHR (0.43) | TSHRNAPRTTDP1ALDH1A1KCNA5 | |
| Dioxane SCHEMBL262902 | 0.88 | TSHR (0.60) | TSHRNAPRTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 170 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3604299-B1 | CHEMICAL COMPOUND USEFUL AS INTERMEDIATE FOR PREPARING A CATECHOL-0-METHYL TRANSFERASE INHIBITOR | BIAL PORTELA & CA SA (PT) | 2023-07-26 | — | — | EP | claimed |
| CN-111544336-A | Sunscreen cream and preparation method thereof | 长沙蓝姿生物科技有限公司 | 2020-08-18 | — | — | CN | claimed |
| EP-3604299-A1 | CHEMICAL COMPOUND USEFUL AS INTERMEDIATE FOR PREPARING A CATECHOL-0-METHYL TRANSFERASE INHIBITOR | Bial-Portela & CA, S.A. (PT) | 2020-02-05 | — | — | EP | claimed |
| CN-105754260-B | A kind of PVC bottle cap sealants of the low amount of moving out and preparation method thereof | 江南大学 | 2017-10-27 | — | — | CN | claimed |
| CN-107137720-A | A kind of preparation method of the new multi-arm polyethylene glycol Nano medication for containing triptolide and HCPT | 北京林业大学 | 2017-09-08 | — | — | CN | claimed |
| CN-106924220-A | A kind of preparation of cancer target multi-arm polyethylene glycol triptolide Nano medication | 北京林业大学 | 2017-07-07 | — | — | CN | claimed |
| CN-105754260-A | Low-migrated-amount PVC bottle cap sealant and preparation method thereof | 江南大学 | 2016-07-13 | — | — | CN | claimed |
| US-9359378-B2 | Substituted oxazolo[3,4-a]pyrazines as pharmaceutcals | BIOLAB SANUS FARMACEUTICA LTDA. (BR) | 2016-06-07 | — | — | US | claimed |
| US-9126988-B2 | Intermediate for preparing a catechol-O-methyltransferase inhibitor | BIAL—PORTELA & CA, S.A. (PT) | 2015-09-08 | — | — | US | claimed |
| US-20140350057-A1 | CHEMICAL COMPOUND USEFUL AS INTERMEDIATE FOR PREPARING A CATECHOL-O-METHYLTRANSFERASE INHIBITOR | BIAL - PORTELA & CA, S.A. (PT) | 2014-11-27 | — | — | US | claimed |
| EP-2791134-A1 | CHEMICAL COMPOUND USEFUL AS INTERMEDIATE FOR PREPARING A CATECHOL-O-METHYLTRANSFERASE INHIBITOR | BIAL - Portela & Cª S.A. (PT) | 2014-10-22 | — | — | EP | claimed |
| WO-2013089573-A1 | CHEMICAL COMPOUND USEFUL AS INTERMEDIATE FOR PREPARING A CATECHOL-O-METHYLTRANSFERASE INHIBITOR | BIAL - PORTELA & Cª., S.A. (PT) | 2013-06-20 | — | — | WO | claimed |
| US-7115590-B1 | Phosphoramidate, and mono-, di-, and tri-phosphate esters of (1R, cis)-4-(6-amino-9H-purin-9-yl)-2-cyclopentene-1-methanol as antiviral agents | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2006-10-03 | — | — | US | claimed |
| EP-1150988-B1 | PHOSPHORAMIDATE, AND MONO-, DI-, AND TRI-PHOSPHATE ESTERS OF (1R, CIS)-4-(6-AMINO-9H-PURIN-9-YL)-2-CYCLOPENTENE-1-METHANOL AS ANTIVIRAL AGENTS | GLAXO GROUP LTD (GB) | 2003-05-28 | — | — | EP | claimed |
| CN-1346360-A | Phosphoramidates and di-and tri-phosphate esters of (1R, cis) -4- (6-amino-9H-purin-9-yl) -2-cyclopentene-1-methanol as antiviral agents | GLAXO GROUP LTD (GB) | 2002-04-24 | — | — | CN | claimed |
| EP-1150988-A1 | PHOSPHORAMIDATE, AND MONO-, DI-, AND TRI-PHOSPHATE ESTERS OF (1R, CIS)-4-(6-AMINO-9H-PURIN-9-YL)-2-CYCLOPENTENE-1-METHANOL AS ANTIVIRAL AGENTS | GLAXO GROUP LIMITED (GB) | 2001-11-07 | — | — | EP | claimed |
| WO-2000047591-A1 | PHOSPHORAMIDATE, AND MONO-, DI-, AND TRI-PHOSPHATE ESTERS OF (1R, CIS)-4-(6-AMINO-9H-PURIN-9-YL)-2-CYCLOPENTENE-1-METHANOL AS ANTIVIRAL AGENTS | GLAXO GROUP LIMITED (GB) | 2000-08-17 | — | — | WO | claimed |
| US-20260049978-A1 | METHODS FOR TREATING CAG REPEAT EXPANSION DISORDERS USING SMALL MOLECULES THAT SELECTIVELY REDUCE EXPANDED CAG TRANSCRIPT LEVELS | UNIV NEW YORK STATE RES FOUND (US) | 2026-02-19 | — | — | US | disclosed |
| US-4181669-A | A CARBODIIMIDE WITH ACID CATALYSTS AS A CONDENSATION AGENT | AKTIEBOLAGET LEO (SE) | 1980-01-01 | — | — | US | disclosed |
| US-4180504-A | Method for the preparation of esters | AKTIEBOLAGET LEO (SE) | 1979-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260049978-A1 | METHODS FOR TREATING CAG REPEAT EXPANSION DISORDERS USING SMALL MOLECULES THAT SELECTIVELY REDUCE EXPANDED CAG TRANSCRIPT LEVELS | HTT, SMN1; SMN2, FUS | TSHR 1704/4885NAPRT 4158/4885TDP1 136/4885 |
| US-20140350057-A1 | CHEMICAL COMPOUND USEFUL AS INTERMEDIATE FOR PREPARING A CATECHOL-O-METHYLTRANSFERASE INHIBITOR | COMT, PNMT, HNMT | TSHR 4213/4885NAPRT 570/4885TDP1 583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.